At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 232 enrolled
Drug / intervention
Oxycodone/Naloxone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxy/Nal Prolonged Release Tablets Compared to Oxy PR in Subjects With Moderate to Severe, Chronic Cancer Pain
In Brief
A Phase 3 clinical trial evaluating Oxycodone/Naloxone and Oxycodone for Cancer and Pain. Completed, enrolled 232 participants across 28 sites.
Detailed Summary
To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain
Study Details
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJun 2013
Primary CompletionAug 2015
Study CompletionDec 2015
TodayJul 2026
First PostedJun 24, 2013
Enrollment StartJun 1, 2013
Primary CompletionAug 30, 2015
Study CompletionDec 30, 2015
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 13.0 years ago
Interventions
Oxycodone/Naloxonedrug
Oxycodonedrug